Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
Aged
CD5 Antigens
/ metabolism
Female
Gene Amplification
Gene Expression Regulation, Neoplastic
Humans
Lymphoma, Large B-Cell, Diffuse
/ epidemiology
Male
Proto-Oncogene Proteins c-bcl-2
/ genetics
Proto-Oncogene Proteins c-myc
/ genetics
Republic of Korea
/ epidemiology
Retrospective Studies
Translocation, Genetic
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
06
2019
accepted:
08
10
2019
entrez:
24
10
2019
pubmed:
24
10
2019
medline:
21
3
2020
Statut:
epublish
Résumé
Aberrant expression of CD5 has been reported in 5-10% of diffuse large B-cell lymphomas (DLBCLs). CD5+ DLBCL had been recognized as an aggressive immunophenotypic subgroup of DLBCL in the 2008 WHO classification of haematolymphoid neoplasm; however, it was eliminated from the list of subgroups of DLBCLs in the revised 2016 classification. Nevertheless, there is much controversy regarding the clinical significance of CD5 expression, and many researchers still assert that this subgroup exhibits an extremely unfavorable prognosis with frequent treatment failure. We retrospectively investigated 405 DLBCLs recruited from three university hospitals in Korea from 1997 to 2013. The clinical profile, immunophenotype, and chromosomal structural alterations of the BCL2 and MYC genes were compared according to CD5 expression. A total of 29 cases of de novo CD5+ DLBCL were identified out of 405 in our series (7.4%). Clinicopathologic correlation was performed in all 29 CD5+ DLBCLs and 166 CD5- DLBCLs which were eligible for full clinical review and further pathologic examination. Compared with CD5- counterparts, CD5+ DLBCLs showed female preponderance, frequent bone marrow involvement, higher lactate dehydrogenase level, advanced Ann Arbor stages and poorer prognosis (all p<0.05). Pathologically, the expression of CD5 positively correlated with that of BCL2, MYC and Ki-67 (all p<0.05). Coexpression of BCL2 and MYC, which is referred to as a double-expressor, was relatively more common in CD5+ DLBCL, whereas translocation or amplification of these genes was very rare. in conclusion, the expression of CD5 is an independent poor prognostic factor of DLBCLs, and this subgroup displays unique clinicopathologic features. Although the exact mechanism remains uncertain, consistent activation of BCL2 and MYC by alternative pathways other than chromosomal translocation may contribute to the pathogenesis.
Identifiants
pubmed: 31644584
doi: 10.1371/journal.pone.0224247
pii: PONE-D-19-18460
pmc: PMC6808439
doi:
Substances chimiques
BCL2 protein, human
0
CD5 Antigens
0
MYC protein, human
0
Proto-Oncogene Proteins c-bcl-2
0
Proto-Oncogene Proteins c-myc
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0224247Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Pathol. 1995 Jul;147(1):207-16
pubmed: 7541611
J Immunol. 1986 Jan;136(2):505-10
pubmed: 2934473
Blood. 2002 Dec 15;100(13):4537-43
pubmed: 12393419
Sci Rep. 2018 Oct 4;8(1):14814
pubmed: 30287880
Mol Cancer Ther. 2017 Oct;16(10):2083-2093
pubmed: 28615297
Hematology. 2019 Dec;24(1):446-454
pubmed: 31072235
Am J Clin Pathol. 2006 Jun;125(6):954-5
pubmed: 16761357
Cancer Res. 2008 Jun 1;68(11):4123-32
pubmed: 18519671
Blood. 2013 Apr 4;121(14):2715-24
pubmed: 23343832
PLoS One. 2017 Feb 17;12(2):e0172364
pubmed: 28212447
Adv Immunol. 1989;47:117-85
pubmed: 2479233
Oncotarget. 2016 Jan 19;7(3):2401-16
pubmed: 26573234
Histopathology. 2016 Feb;68(3):442-9
pubmed: 26100211
Haematologica. 2008 Aug;93(8):1195-202
pubmed: 18556402
Oncotarget. 2015 Jun 10;6(16):14720
pubmed: 26116824
Clin Immunol. 2008 Apr;127(1):14-25
pubmed: 18191619
Haematologica. 2016 Apr;101(4):466-73
pubmed: 26768687
Am J Hematol. 2013 Sep;88(9):798-802
pubmed: 23695956
Blood Rev. 2017 Mar;31(2):37-42
pubmed: 27717585
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Br J Haematol. 1999 Jun;105(4):1133-9
pubmed: 10554834
Cancer. 2017 Apr 1;123(7):1166-1173
pubmed: 27915469
J Hematol Oncol. 2015 Jun 14;8:70
pubmed: 26071053
Leuk Lymphoma. 2010 Jan;51(1):161-3
pubmed: 19863175
Mod Pathol. 2017 Dec;30(12):1688-1697
pubmed: 28776574
Virchows Arch. 2015 Nov;467(5):571-82
pubmed: 26369546
Am J Clin Pathol. 2009 Mar;131(3):339-46
pubmed: 19228640
Am J Clin Pathol. 2000 Oct;114(4):523-33
pubmed: 11026098
Gene. 2012 Feb 25;494(2):145-60
pubmed: 22227497
Lancet Oncol. 2015 Nov;16(15):e555-e567
pubmed: 26545844
Ann Oncol. 2011 Jul;22(7):1601-7
pubmed: 21199885
Hematol Oncol. 2010 Mar;28(1):27-32
pubmed: 19358143
Blood. 2002 Feb 1;99(3):815-21
pubmed: 11806981
J Clin Oncol. 2012 Oct 1;30(28):3452-9
pubmed: 22851565
Mod Pathol. 2016 Nov;29(11):1313-1323
pubmed: 27469333
Am J Hematol. 2016 Jun;91(4):395-9
pubmed: 26800311
Ann Oncol. 2008 Nov;19(11):1921-6
pubmed: 18573805
Eur J Haematol. 2017 Apr;98(4):415-421
pubmed: 28039906
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078